Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
November 1, 1996Antimicrobial Agents and ChemotherapyOpen Access

Comparative antimycobacterial activities of rifampin, rifapentine, and KRM-1648 against a collection of rifampin-resistant Mycobacterium tuberculosis isolates with known rpoB mutations

View Full Paper
Ask AI
Bookmark
Share

Authors

SMSoraya L. MoghazehPfizer (United States)XPX PanZaozhuang UniversityTAT M ArainNovartis (Switzerland)

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Moghazeh et al. (1996) studied this question.

synapsesocial.com/papers/6a7f57d84c8e1ef7ab428161https://doi.org/10.1128/aac.40.11.2655
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Relationship between rifampin MICs for and rpoB mutations of Mycobacterium tuberculosis strains isolated in Japan1996 · 146 citations
  2. 2In vitro bactericidal and in vivo therapeutic activities of a new rifamycin derivative, KRM-1648, against Mycobacterium tuberculosis1996 · 23 citations
  3. 3National Committee for Clinical Laboratory Standards1980 · 14,792 citations
  4. 4Topology of the RNA polymerase active center probed by chimeric rifampicin-nucleotide compounds.1994 · 60 citations
  5. 5Evolution of drug-resistant tuberculosis: a tale of two species.1994 · 73 citations